3.2. Magnetic Resonance Imaging Evaluation of Intratumor Sarcoma-45 Heterogeneity
Sarcoma-45 presented with intermediate to high T
2-weighted signal intensity and a smooth rim with a clear distinction of the margin, as shown in
Figure 3. MRI changes associated with the presence of tumor necrosis and hemorrhage were more pronounced in the IMH group than in the control group. IMH also induced more distinctive tumor capsules. T
2-weighted MRI scans are generally considered sensitive to tissue fluid content. The heterogeneity of pixel distributions in tumor ROIs on T
2-weighted images was previously linked with tumor heterogeneity in soft-tissue sarcomas [
53].
As shown in
Table 3, tumor core ROIs had the highest average brightness and lowest heterogeneity, as opposed to capsule ROIs appearing as regions with the lowest brightness and highest heterogeneity on T
2-weighted images in the control group. IMH produced a 24%, 55% and 48% increase in brightness of core, periphery, and capsule ROIs when compared to the control group, respectively. This can be associated with higher water content and slower blood flow rates given more extensive necrosis [
54,
55]. Another possible reason for the difference between IMH and no-treatment includes the impact of ROS (superoxide radical, hydroxyl radical) and paramagnetic species (molecular oxygen) on T
2 relaxation time and the resulting image brightness [
56]. On average, there was a 22% increase in image heterogeneity of tumor ROIs in the IMH group, as measured by lower Moran’s index (
p < 0.05). Moran’s index did not discriminate core from periphery after IMH treatment, which matched well with US findings in
Table 4.
3.3. Ultrasound Imaging Evaluation of Intratumor Sarcoma-45 Heterogeneity
US examination of sarcoma-45 demonstrated well-defined heterogeneous hypoechoic masses in the subcutaneous tissues. While tumors in the control group tended to show a multinodular growth pattern with a thin capsule separating the lesion from the surrounding tissues (
Figure 4a), IMH treatment mainly resulted in ovoid-shaped tumors with a thicker capsule (
Figure 4c).
Figure 4.
Ultrasound B-mode (a,c) and elastography (b,d) scans of sarcoma-45 on day 24 after tumor implantation ((a,b)—control group; (c,d)—IMH group): 1—tumor core ROI; 2—tumor periphery ROI; 3—tumor capsule ROI.
Figure 4.
Ultrasound B-mode (a,c) and elastography (b,d) scans of sarcoma-45 on day 24 after tumor implantation ((a,b)—control group; (c,d)—IMH group): 1—tumor core ROI; 2—tumor periphery ROI; 3—tumor capsule ROI.
Table 4.
Sarcoma-45 stiffness and heterogeneity in US scans, M ± m.
Table 4.
Sarcoma-45 stiffness and heterogeneity in US scans, M ± m.
Region of Interest | Control Group | IMH Group |
---|
Young’s modulus, kPa |
Tumor core | 35.1 ± 2.3 | 61.5 ± 2.5 a |
Tumor periphery | 50.3 ± 2.4 * | 65.4 ± 4.0 b |
Tumor capsule | 80.6 ± 7.3 *+ | 148.8 ± 10.6 *+c |
Moran’s I, a.u. |
Tumor core | 0.34 ± 0.01 | 0.49 ± 0.01 a |
Tumor periphery | 0.42 ± 0.01 * | 0.49 ± 0.01 b |
Tumor capsule | 0.38 ± 0.01 *+ | 0.29 ± 0.01 *+c |
As shown in
Table 4, core ROIs had the lowest values of Young’s modulus, which occurs due to necrosis formation in the later stages of tumor growth [
57]. On the other hand, tumor capsule ROIs displayed the highest values of Young’s modulus. The stiffness of core, periphery and capsule ROIs was 1.8-fold, 1.3-fold and 1.9-fold higher in the IMH group than in the control group, respectively. Also, IMH led to a 31% and 14% reduction in heterogeneity within tumor core and periphery ROIs as determined by higher Moran’s index (
p < 0.05). Greater heterogeneity was noted in the capsule ROIs on both US and MRI scans. These results mirror previous findings, wherein high T
2 values on MRI positively correlated with tissue stiffness on US shear wave elastography [
58]. Nevertheless, the relationship between imaging features extracted from US and MRI scans cannot be unambiguously summarized owing to the different underlying physical and technical principles of image acquisition.
In agreement with previous observations [
59], the mean blood flow velocity measured using Doppler US in the most proximal vessel adjacent to the tumor capsule (9.87 ± 0.18 cm/s) was nearly three times as much as that of the skeletal muscle vasculature in the intact hindlimb of a healthy rat (3.13 ± 0.03 cm/s). We found a 21% decrease in the flow velocity in response to IMH, given that the last treatment session was delivered 14 days earlier. Vessels surrounding the tumor in the IMH group possessed a 35% higher resistive index than those in the control group (
p < 0.05,
Table 5). This is likely to be explained by vascular damage, compression and increased resistance under the conditions of higher tumor stiffness (
Table 4) [
60]. In addition, a continuous wavelet transform analysis was applied to characterize changes in blood flow waveforms between the groups. Comparing
Figure 5a,b note two higher energy bands around scales 70 and 200–225 as well as a lower energy band around scales 250–300 in the IMH group, which reflect changes in cardiac effects within the 2–6 Hz frequency range on vessel blood flow [
61,
62]. Wavelet energy distribution in the IMH group tended to have lower average energy (2.4 ± 1.3), skewness (0.3) and kurtosis (2.9) values than the control group (energy—2.7 ± 1.9, skewness—1.0; kurtosis—4.1). We cannot exclude the possibility that these results are related to the influence of radiofrequency electromagnetic fields on the cardiovascular system [
63,
64]. Similar to tumor capsule ROIs in US elastography images, Moran’s index of obtained wavelet transform scalograms decreased in animals exposed to IMH (0.87 ± 0.005 a.u.) in comparison to those undergoing no treatment (0.91 ± 0.003 a.u.,
p < 0.05), presumably indicating the relationship between spatial heterogeneity of tumor stiffness and vasculature.
Sarcomas are stiffer than normal muscle or adipose tissues, the biomechanical properties of which are routinely visualized using US elastography [
65]. Activation of cancer-associated fibroblasts and tumor-associated macrophages in the local microenvironment during tumor progression stimulates collagen accumulation, overexpression and cross-linking, resulting in increased stiffness and heterogeneous patterns of the extracellular matrix organization [
66,
67,
68]. As tumors grow, the cells are eventually exposed to a greater degree of mechanical compression, also referred to as solid stress. Importantly, the nonuniformity of solid stress distribution plays a role in mechanochemical transduction signals that regulate cell division and death.
In malignant tumors, chaotic and leaky blood vessels lead to inadequate blood flow and increased interstitial pressure [
69,
70]. Tumor blood vessels on the periphery tend to be better perfused than in core regions. One of the immediate responses to mild hyperthermia is an increase in tumor blood flow caused by elevated flow velocity, dilation or reperfusion of blood vessels [
71]. The combination of IMH with chemotherapy is supported by these considerations in order to target and improve drug delivery to the tumor region. It appears that tumor blood flow increases only temporarily and returns to baseline levels shortly after the treatment session, when the flow distribution follows a less heterogeneous pattern [
72]. Delayed response to radiofrequency-induced hyperthermia can be linked to its ability to damage endothelial cells, inhibit blood vessel formation and lead to impaired blood flow through the tumor after treatment [
73]. In the context of tumor hypoxia, solid stress exerted on tumor vessel walls in the IMH group could not only affect flow rates and distribution of oxygen delivery but also alter the course of mechanochemical reactions that give rise to ROS formation [
74].
3.4. Histological Image Evaluation of Intratumor Sarcoma-45 Heterogeneity
Morphological features observed in sarcoma-45 are summarized in
Table 6. In the control group, tumor core tissue mainly contained eosinophilic cells, numerous apoptotic bodies and necrotic foci (<20% of the section area), while connective tissue fibers were rare (
Figure 6a). In contrast, the tumor core was composed of broad bands of connective tissue fibers in nearly 70% of the section area, large cells with hypochromic nuclei, eosinophilic nonnucleated cells and necrotic foci (<20%) after IMH (
Figure 6b). On the tumor periphery, tissue consisted of large cells with hypochromic nuclei, occasionally observed mitotic figures, large masses of eosinophilic nonnucleated cells and minimal ongoing necrosis (<10%) following no treatment (
Figure 6c). However, in response to IMH, there were extensive masses of necrosis (<50%) infiltrated with eosinophilic nonnucleated cells and commonly observed connective tissue fibers (
Figure 6d). As shown in
Figure 6e,f, the cells also had a 42% lower Ki-67 protein expression in the periphery of the tumor after IMH (53.5 ± 0.1 a.u.) than no-treatment (92.4 ± 0.2 a.u.),
p < 0.05. Histological findings in the capsule of untreated tumors (
Figure 6g) were similar to those on the periphery. The IMH group presented abundant connective tissue fibers observed alone and surrounding necrotic foci (
Figure 6h). These results demonstrate more extensive tumor necrosis, reduced cell proliferation and more pronounced connective tissue replacement in animals subjected to IMH compared to the control group.
Figure 6.
Histological findings observed in sarcoma-45. H&E, ×400. Control group ((a)—tumor core; (c)—tumor periphery; (e)—Ki-67 expression in tumor periphery; (g)—tumor capsule) and IMH group ((b)—tumor core; (d)—tumor periphery; (f)—Ki-67 expression in tumor periphery; (h)—tumor capsule): short arrows—nucleated cells; long arrows—nonnucleated cells and karyorrhexis; arrowhead—mitotic figure; dotted arrows—apoptotic bodies; asterisks—necrotic foci; triangles—connective tissue replacement.
Figure 6.
Histological findings observed in sarcoma-45. H&E, ×400. Control group ((a)—tumor core; (c)—tumor periphery; (e)—Ki-67 expression in tumor periphery; (g)—tumor capsule) and IMH group ((b)—tumor core; (d)—tumor periphery; (f)—Ki-67 expression in tumor periphery; (h)—tumor capsule): short arrows—nucleated cells; long arrows—nonnucleated cells and karyorrhexis; arrowhead—mitotic figure; dotted arrows—apoptotic bodies; asterisks—necrotic foci; triangles—connective tissue replacement.
Table 6.
Histological analysis of sarcoma-45.
Table 6.
Histological analysis of sarcoma-45.
Feature | Control Group | IMH Group |
---|
| Core | Periphery | Capsule | Core | Periphery | Capsule |
---|
necrosis | 1 | 1 | 1 | 1 | 2 | 1 |
apoptosis | 2 | 2 | 0 | 1 | 1 | 0 |
connective tissue replacement | 1 | 0 | 0 | 3 | 3 | 2 |
Total | 4 | 3 | 1 | 5 | 6 | 3 |
With regard to spatial heterogeneity, connective tissue fibers are oriented more uniformly in the normal tissue and treatment-induced fibrosis than in the tumor stroma [
75]. These findings are supported by prior work in which radiation-induced fibrosis had higher stiffness than soft-tissue sarcoma [
76]. In addition, an earlier study reported a two-fold increase in collagen expression and enhanced connective tissue replacement in animals exposed to a 27 MHz electromagnetic field [
77]. Several clinical trials have demonstrated that connective tissue replacement in sarcomas in response to neoadjuvant treatment is associated with a more favorable prognosis [
78].
As shown in
Table 7, IMH treatment reduced image heterogeneity in the tumor core, periphery and capsule, on average, by 21% in comparison with the control group. Furthermore, there was a 25% decrease in heterogeneity of Ki-67 protein distribution measured by higher values of Moran’s index in immunohistochemistry images (
p < 0.05). Consistent with MRI findings (
Table 3) and US elastography (
Table 4), Moran’s index of core and periphery images after IMH did not significantly differ.
Ki-67 is a cell proliferation marker that exhibits a distinct nuclear localization with maximal levels in mitosis and minimal levels in the late G
1 phase of the cell cycle. During mitosis, Ki-67 is enriched on the surface of chromosomes, where it serves as a positively charged electrostatic coating against aggregation of chromosome arms and ensures symmetric distribution of nucleolar components in daughter cells. After mitosis, the protein moves to the nucleolar periphery to assist heterochromatin compaction [
79]. The transition from symmetrical to asymmetrical charge distributions on the macroion surface in complex colloidal systems can considerably modify the electrostatic interactions from repulsion to attraction [
80]. It is not without interest to note that the amplitude of an electrostatic field around protein filaments was calculated to exert forces on the order of pN [
81] and, even more, protein–protein (1–10 pN) and antigen–antibody (10–100 pN) interactions typically require mechanical forces of the same order of magnitude [
82]. Both of these interactions are related to the structural complementarity of one protein molecule with another as a result of numerous conformational state transitions occurring through the direct transformation of chemical energy into mechanical work in such mechanochemical systems [
83]. The electrostatic interactions thus play an important role in mechanochemical effects underlying the formation and heterogeneity of collagen fibrils and Ki-67 domains [
84,
85].
When exposed to radiofrequency electromagnetic fields in the MHz range (i.e., the polarization contribution to dielectric constant is higher than dielectric loss), the rotation of polar and charged side groups in a protein, as well as the orientation of the surrounding water molecules and ions along the applied field direction, can initiate changes in electrostatic interactions and the cross-linking of proteins [
86]. For instance, applying a 300 MHz electromagnetic field initiated stronger electrostatic interactions in proteins by nearly 9% and, at the same time, limited their interactions with the surrounding water by 31% on average, leading to a more compact conformational state [
87].
Therefore, we propose that the observed effects of IMH on sarcoma-45 can be interpreted in terms of changes in the symmetry of charge distribution and electrostatic interactions in biopolymers and the surrounding media under the influence of the applied field, which translate into patterns of intratumor heterogeneity at the molecular, cellular and tissue levels. Such quantitative characterization of intratumor heterogeneity is valuable for guiding theranostic technology in regional hyperthermia for sarcoma patients [
88].
Further research should assess the role of intratumor heterogeneity in image-guided IMH for sarcoma patients in a clinical setting. This will require developing software algorithms and computer models that extract descriptors of intratumor heterogeneity, for example, image histogram characteristics, gray level co-occurrence, run length and size zone matrices, fractal dimension and lacunarity, and tailor IMH parameters, such as the strength of the electric and magnetic fields, SAR, temperature and duration, to extend personalized treatment planning. In addition, by adopting hybrid imaging methods, which combine magnetic resonance imaging, elastography and thermometry, positron emission tomography and computed tomography, it is possible to identify changes in several biophysical parameters, including MRI signal relaxation rate, mechanical stiffness, temperature, metabolite uptake and Hounsfield units, in response to IMH at the same time and thus provide a more comprehensive characterization of intratumor heterogeneity. The major limitation of the present study is the small sample size. We also suggest that future studies should focus on other models, such as sarcoma-180 or Walker-256 carcinosarcoma, as well as different texture features to evaluate image heterogeneity. A natural progression of this work is to investigate the combined effects of IMH with chemotherapy, radiotherapy and immunotherapy, utilizing imaging heterogeneity to initiate a more pronounced antitumor effect in the late phase of tumor growth for patients with advanced sarcomas. It is recommended that more quantitative information be collected to determine the relationship between different manifestations of intratumor heterogeneity at the molecular, cellular and tissue levels by correlating imaging biomarkers, personalized treatment plans and patient outcomes.